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Abstract
Introduction:  Hereditary amyloidodis is a rare disease process with a propensity to cause
polyneuropathies, autonomic dysfunction, and restrictive cardiomyopathy. It is transmitted in an
autosomal dominant manner, with disease onset usually in the 20s-40s. The most common
hereditary amyloidogenic protein, transthyretin, is synthesized in the liver and lies on Chromosome
18. Over 80 amyloidogenic transthyretin mutations have been described, the majority of which are
neuropathic and hence the common name, Familial Amyloidotic Polyneuropathy. Until 1990, the
disease was intractable with a 5–15 year survival after diagnosis. The prognosis changed after the
implementation of orthotropic liver transplantation as a treatment strategy which halts the
synthesis of amyloidogenic transthyretin. This has now has been performed over 1300 times in 67
centers.
Case presentation: We describe the case of a man of Irish ancestry with Familial Amyloidotic
Polyneuropathy and no clinical history of cardiac involvement. Shortly after orthotropic liver
transplantation, he developed congestive heart failure. He was subsequently diagnosed with an
accelerating post-transplant restrictive cardiomyopathy due to amyloid infiltration.
Conclusion: A liver transplant induced cardiomyopathy in Familial Amyloidotic Polyneuropathy
can be observed in patients without any history of cardiac symptoms. All patients with Familial
Amyloidotic Polyneuropathy should be followed after transplantation to assess for a deterioration
in cardiac function.
Introduction
Familial Amyloid Polyneuropathy (FAP) is a disease proc-
ess that has been described to affect the cardiovascular sys-
tem. Clinical manifestations include hypotension,
conduction disturbances, and most problematic, restric-
tive cardiomyopathies [1]. The majority of those with FAP
have bothersome neuropathies, and are spared significant
cardiovascular complications. Orthotropic liver trans-
plantation (OLT) has been shown to stabilize and at times
improve the neuropathic symptoms. Based on the patho-
genesis of FAP, if OLT is performed prior to any of the
clinical manifestations of cardiac amyloidosis, the likeli-
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hood of a patient succumbing to an amyloid cardiomyop-
athy should be significantly decreased.
Case presentation
A 61 year old man presented with increasing dyspnea on
exertion, ascites, and lower extremity edema. His medical
history was remarkable for FAP which initially manifested
ten years earlier as nausea and vomiting due to gastropare-
sis. In addition, he developed a painful peripheral neu-
ropathy approximately two years later. Due to his
progressive symptoms, he underwent OLT at another
institution in August, 2006. Prior to his transplant, he had
no cardiovascular complaints. His preoperative evalua-
tion included a 2-dimensional echocardiogram. He did
not have a cardiac catheterization. Approximately 2
months after his transplant, he began feeling dyspneic
with mild to moderate activity. Shortly thereafter, he
began to develop increasing abdominal girth and lower
extremity edema. He presented to our institution in Feb-
ruary, 2007 with further progression of these symptoms.
His current medications included prednisone, tacrolimus,
gabapentin, clotrimazole, valcyclovir, and pentamadine.
His family history was significant for a father dying in his
50s due to gastrointestinal complications from FAP. On
physical examination his heart rate was 100 with a blood
pressure of 110/60 mmHg. He had an oxygen saturation
of 97% while receiving oxygen at 4 L/min by nasal canula.
He had no evidence of jaundice. He had crackles at the
bases of his lungs bilaterally. His cardiovascular exam was
remarkable for 10 cm of jugular venous distension, a reg-
ular rhythm with no murmurs, and an S4 gallop at the
apex. His abdomen was mildly distended with shifting
dullness to percussion and a liver edge 4 cm below the
right costal margin. He had 2 + bilateral lower extremity
edema. The ECG demonstrated sinus tachycardia with
normal voltage, right axis deviation, and a left posterior
divisional block. The Chest XRAY demonstrated mild car-
diomegaly, patchy infiltration with associated atelectasis
at the lung bases and a small right sided pleural effusion.
The echocardiogram demonstrated an increase in left
atrial volume, but was otherwise unchanged from his pre-
operative echocardiogram. (Table 1) This prompted an
inferiorvenocavogram to evaluate for possible stenosis at
the level of the anastomosis. The pressure gradient across
the inferior vena cava anastomosis was unremarkable at
1–2 mmHg. There was no evidence of portal hyperten-
sion. However, the overall central venous pressure was
elevated at 18–19 mmHg. It was decided at this time to
perform a right and left heart catheterization. The coro-
nary arteries were angiographically normal. The right and
left heart pressures were elevated. (Table 2) His pressure
tracings demonstrated no evidence of intrathoracic-intrac-
ardiac pressure dissociation or ventricular interdepend-
ence. Overall, this pattern was most consistent with
restrictive physiology. An endomyocardial biopsy was
performed which was consistent with cardiac amyloido-
sis. (Figure 1) Subsequently, it was learned that the
patient's mutation was on the transthyretin (TTR) gene,
Threonine60Alanine. He was started on an aggressive diu-
retic regimen and began to feel moderate relief. He is cur-
rently being closely followed as an out-patient and will be
considered for cardiac transplantation if his symptoms
cannot be controlled with medical management.
Discussion
Amyloidosis is a disorder resulting from the abnormal
deposition of a particular protein in various tissues of the
body. The four most common forms of amyloidosis are:
(1)  light chain due to immunoglobulins; (2)  secondary
which is seen in chronic inflammatory states such as rheu-
matoid arthritis; (3) senile which is typically seen in those
over the age of 80; and (4) heriditary. There are at least
eight different proteins that have been recognized to cause
the hereditary amyloidoses [2]. Of these, the amy-
loidgenicTTR (ATTR) protein is the most common, with
the Val30Met (Portuguese type) being the most prevalent
mutation causing ATTR (80% of cases) [2]. The most com-
mon manifestation of ATTR is a neuropathy, but clinical
manifestations vary depending on the location of the
mutation. The treatment of hereditary amyloidosis is OLT,
Table 1: Echocardiograms: Pre- and Post- Liver Transplant
Variable May, 2006 February, 2007
Ejection Fraction 55% 50%
Interventricular Septal Thickness (cm)* 1.5 1.2
Posterior Wall Thickness (cm)* 1.2 1.4
Left Ventricular Hypertrophy Moderate Moderate
Left Atrial Volume Index (cc/m2)** 24 40
Diastolic Dysfunction Grade 2 Grade 2
Right Ventricular Systolic Pressure (mmHg) 25 35
>mild valvular regurgitation No No
Pericardial effusion No Trivial to Small
*Normal Value 0.6–1.1 cm
**Normal Value <28 cc/m2Journal of Medical Case Reports 2008, 2:35 http://www.jmedicalcasereports.com/content/2/1/35
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which limits further synthesis of the mutated protein, and
thus halts further deposition in the organs. The Val30Met
mutation typically presents with neuropathy, cardiac con-
duction disturbances, GI dysfunction, nephrosis and car-
pal tunnel syndrome. The eighty-plus nonVal30Met
mutations in general have a greater propensity to cause
cardiomyopathies [1]. In instances of a concomitant car-
diomyopathy in the setting of FAP, simultaneous heart-
liver transplantation has been performed with some suc-
cess, though the numbers are small [3,4].
What we describe here is a man with no clinical manifes-
tations of a cardiomyopathy prior to OLT who developed
a progressive cardiomyopathy shortly after obtaining a
normal liver. This clinical presentation of rapid and pro-
gressive cardiac amyloidosis following liver transplanta-
tion for FAP has been described by Stangou et al. His
group evaluated 20 patients with FAP, 14 of whom under-
went OLT, and compared their post-operative cardiac
course with 10 traditional cirrhotic patients who under-
went OLT. He found that in the group of FAP patients
with OLT, there was a significant change in mean inter-
ventricular septal thickness in the 5 patients with
nonVal30met mutations (15.2 mm progressed to 21.5
mm over 3 months, p < 0.05). There was no significant
change in those with Val30Met mutations who underwent
OLT, those with FAP who did not receive a liver or in the
patients with traditional cirrhosis after OLT. In addition,
2 of the nonVal30Met patients were dead at 3 months due
to heart failure [5]. Of interest, Olofsson et al also demon-
strated progressive ventricular thickness in a group of FAP
patients post-OLT with the more common Val30Met
mutation, though the degree of ventricular hypertrophy
was not as dramatic as was seen in Stangou's populatin
(mean IVS thickness 11.5 mm before OLT and 13.1 mm
at 18 months) [6].
The current hypothesis as to why this may occur has been
looked at by previous investigators. Biochemical evidence
suggests that before OLT, variant TTR-derived amyloid
fibrils form a template to which wild type TTR attaches to
after OLT. Yazaki et al studied 6 patients with FAP and evi-
dence of cardiac involvement. Amyloid fibrils of the heart
were composed of wild-type TTR as well as variant TTR at
a ratio of about 1:1 in 5 patients without liver transplan-
tation. In the patient with a transplanted liver, about 80%
of the cardiac amyloid consisted of wild-type TTR [7]. He
concluded that wild-type TTR contributes greatly to the
development of amyloid deposition in the heart of FAP
patients after OLT. This hypothesis is still considered by
most experts to be the most likely explanation for the
underlying pathophysiology. Interestingly, our patient
unquestionably developed a rapid progressive cardiomy-
opathy following OLT, though with minimal change in
overall myocardial thickness when compared to the pre-
OLT echocardiogram. There was however a significant
degree of change in left atrial volume. We postulate that
the amyloid deposition may cause significant pathologi-
cal changes on a cellular level leading to restriction, before
there is macroscopic evidence of increasing ventricular
thickness.
Conclusion
Therefore, the results to date indicate that paradoxical
wild-type TTR deposition after OLT can preferentially
occur in myocardium, leading to even fatal cardiac dys-
function. What are the long-term implications? Essen-
tially, the long-term outcome after OLT in FAP is still
unknown. Although malnutrition, neuropathy, and renal
insufficiency may be ameliorated, there is concern that an
accelerating restrictive cardiomyopathy may limit sur-
vival. FAP patients with Val30Met and especially those
with nonVal30Met mutations must be followed by
a. (Left) H&E. Higher power shot Figure 1
a. (Left) H&E. Higher power shot. Eosinophilic amorphous 
material separating myocytes with angulation of myocytes 
consistent with amyloidosis. b. (Right) Trichrome stain. Col-
lagen around blood vessel (lower right corner) is blue, mate-
rial surrounding myocytes is grey characteristic of amyloid. 
Interstitial material exhibited apple-green birefringence under 
polarized light with Congo red staining. (Not shown)
Table 2: Right Heart Catheterization Pressures
RA RV PA PCWP LV AO
16 65/9 63/32 37 155/9 154/82
-RA = Right Atrium, RV = Right Ventricle, PA = Pulmonary Artery, 
PCWP = Pulmonary Wedge Pressure, LV = left Ventricle, AO = 
Aortic Pressure
-Pressures are recorded in mmHg
-Normal Mean Values: RA (3 mm Hg), RV (25/4 mm Hg), PA (25/9 
mm Hg) PCWP (9 mm Hg), LV (130/8 mm Hg), AO (130/70 mm Hg)Publish with BioMed Central    and   every 
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echocardiography on a regular basis after OLT to enable
an identification of individuals with increasing cardiomy-
opathy. However, as was seen in our patient, an acceler-
ated cardiomyopathy may present clinically before there
is echocardiographic evidence of amyloid deposition.
This finding should urge physicians to measure cardiac
hemodynamics in this setting, especially when there is no
significant change in ventricular thicknesss. Echocardiog-
raphy with Doppler can be useful, but in our case, the
diagnosis was made with cardiac catheterization. With
more data, combined heart and liver transplantation
might be considered as an initial management strategy,
even in those with a non existent or a subclinical cardiomy-
opathy. Alternatively, a new medical trial such as stabili-
zation of wild-type TTR and/or reduction of the amount
of substrate available for amyloid formation using anti-
sense oligonucleotides may in the future be therapeutic
options for FAP patients, before and after OLT [8-10].
Abbreviations
1. FAP: Familial Amyloid Polyneuropathy




The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors were involved with the writing/reviewing of
the manuscript. All authors approved the final manu-
script.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Acknowledgements
Full written consent has been obtained by the patient for the submission of 
this manuscript for publication. Funding was neither sought nor obtained.
References
1. Shu-ichi Ikeda, Masamitsu Nakazato, Yukio Ando, Gen Sobue: Famil-
ial transthyretin-type polyneuropathy in Japan: Clinical and
genetic heterogeneity.  Neurology 58(7):1001-1007. April 9, 2002
2. Saraiva MJ: Sporadic Cases of Heriditary Systemic Amyloido-
sis.  The New England Journal of Medicine 346(23):118-119. 2002 June
6
3.  [http://www.fapwtr.org].
4. Grazi G, Cescon M, Fabrizio S, Ercolani G, Ravaioli M, Arpessela G,
Magelli C, Grigioni F, Cavallari A: Combined Heart and Liver
Transplantation for Familial Amyloidotoc Neuropathy: Con-
siderations From the Hepatic Point of View.  Liver Transplanta-
tion 2003, 9(9):986-92.
5. Stangou A, Hawkins P, Heaton N, Rela M, Monaghan M, Nihoyannop-
oulos P, O'Grady J, Pepys M, Williams P: Progressive Cardiac
Amyloidosis Following LiverTransplantation For Familial
Amyloid Polyneuropathy: Implications for Amyloid Fibrillo-
genesis.  Transplantation 66(2):229-233. July 27, 1998
6. Olofsson B, Backman C, Kmap K: Progression of cardiomyopa-
thy after liver transplantation in patients with familial amy-
loidotic polyneuropathy, portuguese type.  Transplantation
73(5):745-751. March 15, 2002
7. Yazaki M, Tokuda T, Nakamura A, Higuchi K, Harihara Y, Baba S,
Ikeda S: Cardiac Amyloid in Patients with Familial Amyloid
Polyneuropathy Consists of Abundant Wild-Type Transthy-
retin.  Biochem Biophys Res Commun 2000, 274:702-706.
8. Miller SR, Sekijima Y, Kelly JW: Native state stabilization by
NSAIDs inhibits transthyretin amyloidogenesis from the
most common familial disease variants.  Lab Invest 2004,
84:545-552.
9. Sato T, Ando Y, Susuki S, Nakamura A, Mikami F, Kai H: Chromium
(III) ion and thyroxine cooperate to stabilize the transthyre-
tin tetramer and suppress in vitro amyloid fibril formation.
FEBS Let 2006, 580:491-496.
10. Benson M, Kluve-Beckerman B, Zeldenrust SR: Targeted suppres-
sion of an amyloidogenic transthyretin with antisense oligo-
nucleotides.  Muscle Nerve 2006, 33:609-618.